ChinaDaily Briefs

Daily Brief China: Vcanbio Cell & Gene Engineering, KE Holdings and more

In today’s briefing:

  • Quiddity Leaderboard CSI Medical Jun25: Three ADDs/DELs Likely; >2x ADV to Trade for Most Names
  • [KE Holdings (BEKE US, BUY, TP US$25) Earnings Review]: Housing Inventory Resolution Drives Recovery


Quiddity Leaderboard CSI Medical Jun25: Three ADDs/DELs Likely; >2x ADV to Trade for Most Names

By Janaghan Jeyakumar, CFA

  • The CSI Medical Index represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical themes in China.
  • In this insight, we take a look at the potential ADDs and DELs leading the race for the semiannual index rebal event in June 2025.
  • We expect up to three ADDs and three DELs in June 2025 based on the latest available data (where 90% of the reference period is complete).

[KE Holdings (BEKE US, BUY, TP US$25) Earnings Review]: Housing Inventory Resolution Drives Recovery

By Eric Wen

  • Beike reported C4Q24 revenue beat our estimate/consensus by 8.4%/7.4%, non-GAAP OP miss our estimate/consensus by 37.5%/21.6%, due to front-loading expansion cost.
  • We expect Beike to take 2-3ppt of market share in a rebalancing property market in 2025. 
  • We keep the stock as BUY and keep TP at US$25.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars